Final OS results of IMvigor130: Atezolizumab plus platinum gemcitabine for mUC from statistical significant results Watch Video
Preview(s):
Gallery
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
Description: Prof Matt Galsky speaks to ecancer about the final overall survival results from the randomised phase 3 IMvigor130 study at ASCO GU 2023.nnThe IMvigor130 primary analysis demonstrated statistically significant PFS benefit with 1L atezo + plt/gem (Arm A) versus placebo + plt/gem (Arm C) in patients with metastatic urothelial carcinoma.nnHowever, in the final analysis, the results demonstrated the improved OS with atezo + plt/gem versus placebo + plt/gem did not reach statistical significance in I
Play Video: (Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)